ADAyşe Rumeysa Aydoğan Demir

Ayşe Rumeysa Aydoğan Demir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayşe Rumeysa Aydoğan Demir has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic and clinicopathologic significance of the tumor–stroma ratio in pure endometrial serous carcinoma

    by Teyfik Demir, Zafer Kiraz, Canan Çolak, Ayşe Rumeysa Aydoğan Demir, Melih Akpunar, Güzin Demirağ, Mehmet Kefeli

  • Open Access

    Prognostic significance of folate receptor alpha expression in endometrial serous carcinoma: implications for patient stratification and targeted therapy

    by Teyfik Demir, Seda Nur Okur, Ayşe Rumeysa Aydoğan Demir, Güzin Demirağ, Mehmet Kefeli

    Objective: To evaluate the clinical significance of folate receptor alpha (FRα) expression in endometrial serous carcinoma. Methods: We retrospectively analyzed 47 patients with histopathologically confirmed endometrial serous carcinoma who underwent hysterectomy and received systemic therapy. FRα expression was assessed by immunohistochemistry and categorized as high or low based on ≥ 25% of tumor cells showing moderate-to-strong membranous staining. Associations with clinicopathological variables and survival outcomes were evaluated. Results: High FRα expression was observed in 29.8% of cases and was not associated with clinicopathological variables. Patients with high FRα expression had significantly shorter progression-free survival compared with those with low expression (median, 14 vs. 54 months; p = 0.007). In multivariable Cox regression analysis for PFS, high FRα expression remained independently associated with shorter PFS (HR 3.91, 95% CI 1.54–9.94, p = 0.004). No statistically significant difference in overall survival was observed ( p = 0.08). Conclusion: High FRα expression was associated with shorter progression-free survival in endometrial serous carcinoma. These findings suggest that FRα expression may represent a biologically relevant marker associated with disease progression and support further investigation in molecularly characterized cohorts.

  • Open Access

    Olgularla Kadın Hastalıkları ve Doğum II

    by Arzu Bostancı Durmuş, Burak Barutcu, Betül Akgün Aktaş, Gizem Toker, Hatice Laçin Tuğan, Ruken Dayanan, Kübra Dilşad Sönmez Özgür, Engin Korkmazer, Beyzanur Kahyaoğlu, Cuma Taşın, et al.

  • Open Access

    Kemik İliği Transplantasyonu Sonrası Graft-Versus-Host Hastalığı ile İlişkili Vajinal Stenoz

    by Ayşe Rumeysa Aydoğan Demir

    Graft versus host hastalığı (GVHD) normal dokuya karşı immünolojik bir reaksiyondur ve allojenik kök hücre naklinin bir komplikasyonu olarak ortaya çıkabilir. Genital GVHD, allojenik kemik iliği transplantasyonunun (KİT) daha az bilinen ve muhtemelen hafife alınan bir komplikasyonudur (1). GVHD' e neden olan mekanizma graft hücrelerin konakçı hücrenin anjijenlerine karşı geliştirdiği T lenfosit immun cevabıdır (2). GVHD akut veya kronik olabilir. Akut GVHD nakilden sonraki ilk 100 günde, kronik GVHD ise 100 günden sonra meydana gelir (3). GVHD cilt, mukoza, gastrointestinal sistem, karaciğer ve akciğer tutulumu ile seyreden heterojen klinik bulgular gösterir. Kadınlarda GVHD ilişkili immunolojik reaksiyonlara sekonder genital sistemde sklerotik değişiklikler ve mukoza anormallikleri meydana gelebilir (4). Genital GVHD tedavisinde, topikal östrojen preparatları, güçlü topikal kortikosteroidler, immünmodülatör ajanlar, vajinal dilatatörler gibi yöntemler ilk basamakta yer alır. Semptomların ilerlediği veya vajinal stenozun geliştiği olgularda cerrahi müdahale gündeme gelebilir (